Global Hypertension Drugs Market 2014-2018

Reportstack Announces the Publication of its Research Report - Global Hypertension Drugs Market 2014-2018. The following companies are the key players in Global Hypertension Drugs Market: Actelion Ltd., AstraZeneca plc , Boehringer Ingelheim GmbH , Novartis AG , Pfizer Inc., Sanofi SA, Bayer AG , Daiichi SankyoCo. Ltd., Forest Laboratories Inc., Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., United Therapeutics Corp., Valeant Pharmaceuticals International Inc., XOMA LLC.

“The Global Hypertension Drugs market is experiencing a shift toward combination products, using two or more combination treatments. A combination of hypertension therapy with separate agents or a fixed-dose combination pill lowers BP at a faster pace, helps in reaching the target BP, and decreases adverse effects. Additional benefits may include cost savings and better compliance. Moreover, antihypertensive agents from different classes may balance adverse reactions from each other. For instance, for hypertensive patients with diabetes, the recommended treatment includes diuretics, beta blockers, ACE inhibitors, ARBs, and/or CCBs. The Joint National Committee guidelines have recommended diuretics and ACE inhibitors for recurrent stroke prevention in patients with hypertension; beta blockers, ACE inhibitors, and aldosterone antagonists for hypertensive patients who are post myocardial infarction; and ACE inhibitors and ARBs for hypertensive patients with chronic kidney disease.”

According to the report, the Global Hypertension Drugs market is driven by several factors, of which an increase in aging population is one of the major drivers. There is a natural tendency for BP to rise with age due to the reduced elasticity of the arterial system. The promising hypertension drug pipeline is another major driver. The clinical pipeline for hypertension drugs is moderately strong with more emerging therapies.

Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth, as the shift toward lower-priced drugs will lead to a drop in the market valuation for that drug, thereby reducing the overall market value.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit